More than two-thirds of people with an advanced form of a rare skin cancer are on track to survive at least two years after starting an immunotherapy drug on a landmark clinical trial, researchers
An immunotherapy clinical trial based in Seattle, among other U.S. sites, was pivotal to the Dec.
Frisco, Texas, resident Steve Murphy, 66, was diagnosed last September with Merkel cell carcinoma, a rare skin cancer he’d never heard of. His grim prognosis: 50 percent chance of surviving 90 days.
The number of U.S. cases of Merkel cell carcinoma, an often-fatal skin cancer, is rising about six times faster than most other cancers and at nearly twice the rate of the more-common melanoma.
Many patients with advanced Merkel cell carcinoma who received the immunotherapeutic pembrolizumab as first-line therapy in a